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Reactions of diastereochemically varied norbornene-condensed 2-thioxopyrimidin-4-ones 6 and 10 with
variously functionalized hydrazonoyl chlorides 2a–h gave regioselectively angular norbornene-based
[1,2,4]triazolo[4,3-a]pyrimidin-7(1H)-ones 7a–h and 11a,c–e, respectively. Thermal retro Diels–Alder
(RDA) reaction of 7a–h and 11a,c–e resulted in the target compounds 4a–h as single products. On the
other hand, reactions of thiouracil 1 and hydrozonoyl chlorides 2a–e gave regioselectively [1,2,4]triazolo
[4,3-a]pyrimidinone-5(1H)-ones 3a–e. The opposite regioselectivity of thiouracil 1 and norbornene-
condensed 2-thioxopyrimidin-4-ones 6 and 10 was attributed to electronic factors according to DFT
calculations. The angular structure of norbornene based [1,2,4]triazolo[4,3-a]pyrimidin-7(1H)-ones was
confirmed by single crystal X-ray crystallography.Introduction
Fused pyrimidines are important compounds, because of their
wide spectrum of biological and pharmacological applica-
tions.1–4 Compounds bearing the [1,2,4]triazolo[4,3-a]pyr-
imidinone ring system were reported to possess a wide range of
pharmacological activities including antitumor,5 antiallergic,6
antimicrobial,7 and 5a-reductase inhibitor properties.8
Hydrazonoyl halides, known since 1930, have attracted the
interest of synthetic chemists in designing and synthesizing
different heterocycles.9 For example, [1,2,4]triazolo[4,3-a]pyr-
imidinones decorated with different functionalities can be
incorporated into 2-thioxopyrimidin-4-ones by reacting the
latter with the appropriate hydrazonoyl halide in the presence
of a base.10 To the best of our knowledge, the reported reactions
of thiouracil derivatives with hydrazonoyl chlorides gave
substituted [1,2,4]triazolo[4,3-a]pyrimidin-5(1H)-ones in
a regioselective manner.11–15
Recently, synthetic chemists have utilized RDA protocols for
designing and synthesizing novel heterocyclic scaffolds. This
method is highly efficient to build a double bond into the
heterocyclic system.16–23
In the present work, we report the formation of novel [1,2,4]
triazolo[4,3-a]pyrimidin-7(1H)-ones 4a–h by reactingiversity of Szeged, Eötvös u. 6, H-6720
u.eg; fulop@pharm.u-szeged.hu
Assiut University, Assiut, 71516, Egypt
skulä, FIN-40014, Jyväskulä, Finland
(ESI) available. CCDC 1980577 and
a in CIF or other electronic format see
f Chemistry 2020norbornene-condensed 2-thioxopyrimidin-4-ones 6 and 10 with
hydrazonyl chlorides 2a–h with various functionalities followed
by applying the RDA protocol. Note that 4a–h, cann't accessible
signicantly from the reactions of thiouracil with hydrazonoyl
chlorides.Results and discussion
The reaction of thiouracil 1 with varied functionalized hydra-
zonoyl chlorides 2a–e gave, as described earlier,11–15 [1,2,4]Scheme 1 Solvents and conditions: dioxane, TEA, reflux 4–6 h. The
ratio of compounds 3 : 4 was calculated from the 1H-NMR spectrum
of the crude reaction mixture using the signals at around 6.1 ppm and
6.5 ppm for H-6 of regioisomers 3 and 4, respectively. Separation of
the regioisomers by column chromatography, eluent: EtOAc, Rf ¼ 3:
0.4; 4 : 0.05.
RSC Adv., 2020, 10, 33937–33943 | 33937
Scheme 2 Solvents and conditions: (i) CSCl2, NaHCO3, CHCl3;27 (ii) NH3, MeOH;27 (iii) dioxane, TEA, reflux, 4–6 h; (iv) MW: in 1,2-DCM, 200 C,
30–120 min, 200 W.
Table 1 Energy difference (kJ mol1) between angular regioisomers 7,11 and their linear counterparts 8,12. Isolated yields of angular
regioisomers 7,11 were given
Entry Energy difference DEa kJ mol1 Yieldb % Entry Energy difference DEa kJ mol1 Yieldb %
7a 50.75 66 7g 50.7 68
8a 8g
7b 51.32 69 7h 47.75 67
8b 8h
7c 47.48 60 11a 51.13 72
8c 12a
7d 61.58 60 11c 46.07 75
8d 12c
7e 38.84 45 11d 58.16 70
8e 12d
7f 62.89 77 11e 44.58 50
8f 12e
a Energy calculations were performed at the density functional theory (DFT) using the B3LYP functional. The 6-311G(d,p) basis sets were employed
on all atoms. b The yield of isolated pure [1,2,4]triazolo[4,3-a]pyrimidin-7(1H)-ones by column chromatography.

































































































View Article Onlinetriazolo[4,3-a]pyrimidin-5(1H)-ones 3a–e as the major and
[1,2,4]triazolo[4,3-a]pyrimidin-7(1H)-ones 4a–e as the minor
products. The ratio of 3a–e and 4a–e was 8–2 : 1 (Scheme 1). The
regioisomers could be easily separated by column chromatog-
raphy via elution with EtOAc.
The challenge hence is how to have 4a–e as major products.
Since 2-thioxopyrimidin-4-one 6 condensed to norbornene can
easily be converted to thiouracil 1 by the RDA strategy,24 we used
6 instead of thiouracil 1 in the reaction with hydrazonoyl
chlorides 2a–h (Scheme 2). Strikingly, the regioselectivity of the
reaction was inversed. Only angular regioisomers, [1,2,4]tri-
azolo[4,3-a]pyrimidin-7(1H)-ones 7a–h, were formed and iso-
lated in moderate yields (Table 1).
In a similar manner, the reaction of diendo norbornene-
condensed 2-thioxopyrimidin-4-one 10 with functionalized
hydrazonoyl chlorides 2a,c–e was also found to be regioselective
towards the formation of angular regioisomers, [1,2,4]triazolo
[4,3-a]pyrimidin-7(1H)-ones 11a,c–e (Scheme 2) (Table 1). The
effect of norbornene on the stereochemical outcome was
attributed to electronic, rather, than steric factors. Specically,
the C]C bond in thiouracil enforces the reaction towards the33938 | RSC Adv., 2020, 10, 33937–33943formation of [1,2,4]triazolo[4,3-a]pyrimidin-5(1H)-ones 3a–e
because (i) the nitrogen located closer to the C]C double bond
is more basic and (ii) tautomeric structure 1A is thermody-
namically more stable than 1B (Scheme 3).rides 2 to form regioisomers 3 and 4.
This journal is © The Royal Society of Chemistry 2020
Scheme 4 Isomerization of hydrazonoyl chlorides (2e as an example).
Fig. 1 Optimized geometric structure and HOMO energy levels of

































































































View Article OnlineThe lower yields of the reactions specially with hydrazonoyl
chloride 2e was ascribed to the tendency of hydrazonoyl chlo-
rides, whose conguration is Z,25 to isomerize to its E isomer
under the reaction conditions as was deduced from the NMR
spectra of the separated side product (ESI†). E isomer of
hydrazonoyl chloride is more stable by hydrogen bonding and is
hindered to be attacked by thione 6,10 to replace its chlorine
atom (Scheme 4).
Aer heating in 1,2-dichlorobenzene (1,2-DCB) at 200 C
under microwave conditions, norbornene-fused triazolo[4,3-a]
pyrimidin-7(1H)-ones (7a–h and 11a,c–e) underwent RDA reac-
tion producing triazolo[4,3-a]pyrimidin-7(1H)-ones 4a–h in
moderate yields in a short time (30–90 minutes, Scheme 2 and
Table 2). The RDA reaction was monitored by TLC and could
also be noticed by the odor of cyclopentadiene. RDA reactions of
diexo isomers are easier than their diendo counterparts (entries
6–9) due to higher stability of diendo isomers as was conrmed
from DFT calculations (ESI†).
Geometry optimization and total energies calculations were
performed at the density functional theory (DFT) using Becke's
three-parameter Lee–Yang–Parr (B3LYP) exchange functional
with 6-311G(d,p) basis sets, using Gaussian-09 program.26
Angular regioisomers 7a–h and 11a,c–e are thermodynamically
more stable than their linear counterparts 8a–h and 12a,c–e,
respectively (Table 1).
Fig. 1 shows the electron distribution and relative stability of
tautomers A and B. The C]C bond (such as in thiouracil)
directs the tautomerism towards an excess of A. When it is
absent (such as in 6,10), the tautomeric equilibrium is shiedTable 2 MW process for the synthesis of triazolo[4,3-a]pyrimidin-7(1H)-
Entry Starting material Product
1 7a (exo) 4a
2 11a (endo)
3 7b (exo) 4b
4 7c (exo) 4c
5 11c (endo)
6 7d (exo) 4d
7 11d (endo)
8 7e (exo) 4e
9 11e (endo)
10 7f (exo) 4f
11 7g (exo) 4g
12 7h (exo) 4h
a T ¼ 200 C, Pmax ¼ 200 W, in 1,2-DCB. b Aer column chromatography.
This journal is © The Royal Society of Chemistry 2020towards B. Tautomer A is responsible for the formation of linear
triazolo[4,3-a]pyrimidin-5(1H)-one regioisomers, while
tautomer B leads to the formation of angular triazolo[4,3-a]
pyrimidin-7(1H)-one regioisomers.
A conclusive evidence for the angular stereochemistry of the
products of the reaction of norbornene-condensed 2-
thioxopyrimidin-4-one 6,10 with hydrazonoyl chlorides 2a–h
was obtained by X-ray crystallographic analysis of compounds
7e and 11d (Fig. 2 and 3).Experimental section
Materials and methods
NMR spectra were recorded at 500.20 MHz for 1H-NMR and at
125.62 MHz for 13C-NMR in CDCl3 at room temperature, using
a Bruker AV NEO Ascend 500 spectrometer (Bruker Biospin,
Karlsruhe, Germany) with Double Resonance Broad Band Probe
(BBO). Tetramethylsilane (TMS) was used as internal standard.
Microwave-promoted reactions were performed using sealed
reaction vials (10 mL) in a microwave (CEM, Discover, SP) cavity
(CEM Corporation, Matthews, NC, USA). Reactions were moni-
tored by thin layer chromatography (TLC) using aluminum
sheets coated with silica gel (POLYGRAM®SIL G/UV254, Merck).
TLC plates were inspected under UV light. Melting points were
measured with a Hinotek-X4 micro melting point apparatusones 4a–h under the optimized reaction conditions
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Fig. 2 TELP image of 7e at 50% probability level. There are two

































































































View Article Online(Hinotek, Ningbo, China) and are uncorrected. All theoretical
calculations were performed using the Gaussian 09 package.
The geometrical optimization was performed at the density
functional theory (DFT) using the B3LYP. The 6-311G(d, p) basis
sets were employed by all atoms.
Diexo 6 and diendo 10 norbornene-fused 2-thioxopyrimidin-
4-ones were prepared from the corresponding norbornene
amino ester 5 and 9, respectively, according to the reported
procedures.27 Hydrazonoyl chlorides 2a–h were synthesized
according to the reported procedures.28–30
X-ray diffraction data of 7e and 11d were collected on
a Rigaku Oxford Diffraction Supernova diffractometer using Mo
Ka (7e) or Cu Ka (11d) radiation. The CrysAlisProX soware
package31 was used for cell renements and data reductions.
The structures were solved by intrinsic phasing method using
the SHELXX soware.32 The data was corrected with empirical
absorption correction based of equivalent reections (7e) or
analytical absorption correction (11d) CrysAlisProX structural
renements31 were carried out using SHELXLX soware.32 The
NH hydrogen atoms were located from the difference Fourier
map and rened isotropically. Other hydrogen atoms were
positioned geometrically and constrained to ride on their
parent atoms, with C–H ¼ 0.95–1.00 A and Uiso ¼ 1.2–1.5UeqFig. 3 TELP image of 11d at 50% probability level.
33940 | RSC Adv., 2020, 10, 33937–33943(parent atom). The crystallographic details are summarized in
Table S7.†General procedure for the synthesis of [1,2,4]triazolo-[4,3-a]
pyrimidin-5(1H)-ones 3a–e and 5,8-methano[1,2,4]-triazolo
[4,3-a]quinazolinones 7a–h and 11a,c–e
To a mixture of 0.5 mmol of 2-thioxopyrimidin-4-one (1,6,10)
and 0.5 mmol of hydrazonyl chloride 2a–h in dioxane (10 mL),
100 mL triethyl amine (TEA) were added. Themixture was heated
under reux conditions with stirring until completion of the
reaction as conrmed by the disappearance of H2S odor and
TLC monitoring (n-hexane/EtOAC ¼ 2 : 1 as the eluent). The
solvent was evaporated under reduced pressure, the residue was
dissolved in CHCl3 (50 mL) and extracted with water (3  10
mL). Then the CHCl3 layer was dried on Na2SO4, the solvent was
evaporated, and the residue was dissolved in 5 mL EtOAc and
puried by column chromatography on silica gel eluted by
EtOAc. In the reaction of thiouracil 1 with hydrazonoyl chloride
2a–e, the major 3a–e and minor 4a–e regioisomers were sepa-
rated using TLC on silica gel (eluent EtOAc): 3a–e, Rf 0.4, 4a–e Rf
0.05. The products were crystallized from Et2O to produce white
or light yellow crystals.
Ethyl 5-oxo-1-phenyl-1,5-dihydro[1,2,4]triazolo[4,3-a]
pyramidine-3-carboxylate (3a). Yield 45%, mp 116–120 C, 1H
NMR (500 MHz, CDCl3) d 8.13 (d, J¼ 7.6 Hz, 2H, Ar.), 8.06 (d, J¼
6.5 Hz, 1H, H-7), 7.61–7.49 (m, 2H, Ar.), 7.42 (t, J ¼ 7.5 Hz, 1H,
Ar.), 6.14 (d, J ¼ 6.6 Hz, 1H, H-6), 4.60 (q, J ¼ 7.2 Hz, 2H,
CH2CH3), 1.48 (t, J ¼ 7.2 Hz, 3H, CH2CH3). 13C NMR (126 MHz,
CDCl3) d 156.6(C]O), 155.9(CH), 155.3(C]O), 147.9(C),
136.2(C), 135.9(C), 129.5(CH), 128.1(CH), 121.1(CH), 103.2(CH),
64.1(CH2), 13.9(CH3).
Ethyl 5-oxo-1-(p-tolyl)-1,5-dihydro[1,2,4]triazolo[4,3-a]
pyramidine-3-carboxylate (3b). Yield 43%, mp 175–176 C, 1H
NMR (500 MHz, CDCl3) d 8.04 (d, J ¼ 6.5 Hz, 1H, H-7), 7.96 (d, J
¼ 8.5 Hz, 2H, Ar.), 7.33 (d, J¼ 8.2 Hz, 2H, Ar.), 6.11 (d, J¼ 6.5 Hz,
1H, H-6), 4.59 (q, J ¼ 7.2 Hz, 2H, CH2CH3), 2.42 (s, 3H, p-tolyl),
1.47 (t, J ¼ 7.2 Hz, 3H, CH2CH3). 13C NMR (126 MHz, CDCl3)
d 156.7(C]O), 155.9(CH), 155.4(C]O), 147.8(C), 138.3(C),
135.7(C), 133.7(C), 129.9(CH), 121.2(CH), 102.9(CH), 64.0(CH2),
21.1(CH3, p-tolyl), 13.9(CH3).
Ethyl 1-(4-nitrophenyl)-5-oxo-1,5-dihydro[1,2,4]triazolo
[4,3-a]pyrimidine-3-carboxylate (3c). Yield 48%, mp 165–168 C,
1H NMR (500 MHz, CDCl3) d 8.55 (d, J¼ 9.4 Hz, 2H, Ar.), 8.41 (d,
J ¼ 9.4 Hz, 2H, Ar.), 8.08 (d, J ¼ 6.6 Hz, 1H, H-7), 6.22 (d, J ¼
6.6 Hz, 1H, H-6), 4.61 (q, J ¼ 7.2 Hz, 2H, CH2CH3), 1.49 (t, J ¼
7.2 Hz, 3H, CH2CH3).
13C NMR (126 MHz, CDCl3) d 156.2(C]O),
155.4(CH), 154.9(C), 147.9(C), 146.1(C), 141.1(C), 136.7(C),
125.1(CH), 120.3(CH), 104.8(CH), 64.4(CH2), 13.9(CH3).
5-Oxo-N-phenyl-1-(p-tolyl)-1,5-dihydro[1,2,4]triazolo[4,3-a]
pyramidine-3-carboxamide (3d). Yield 52%, mp 213–214 C, 1H
NMR (500 MHz, CDCl3) d 13.36 (s, 1H, NH), 8.16 (d, J ¼ 6.2 Hz,
1H, H7), 8.04 (d, J¼ 8.5 Hz, 2H, Ar.), 7.82 (dd, J¼ 8.6, 1.0 Hz, 2H,
Ar.), 7.42–7.37 (m, 2H, Ar.), 7.35 (d, J ¼ 8.2 Hz, 2H, Ar.), 7.18 (t, J
¼ 7.4 Hz, 1H, Ar.), 6.29 (d, J ¼ 6.2 Hz, 1H, H-6), 2.43 (s, 3H, p-
tolyl). 13C NMR (126 MHz, CDCl3) d 159.0(C]O), 156.8(CH),

































































































View Article Online129.9(CH), 129.1(CH), 125.2(CH), 122.0(CH), 120.4(CH),
102.8(CH), 21.2(CH3, p-tolyl).
3-Acetyl-1-(p-tolyl)-[1,2,4]triazolo[4,3-a]pyrimidin-5(1H)-one
(3e). Yield 42%, mp 120–125 C, 1H NMR (500 MHz, CDCl3)
d 8.04 (d, J ¼ 6.5 Hz, 1H, H-7), 7.98 (d, J ¼ 8.6 Hz, 2H, Ar.), 7.35
(d, J¼ 8.2 Hz, 2H, Ar.), 6.16 (d, J¼ 10.5 Hz, 1H, H-6), 2.82 (s, 3H,
COCH3), 2.43 (s, 3H, p-tolyl).
13C NMR (126 MHz, CDCl3)
d 186.3(C]O), 155.6(C]O), 155.5(CH), 148.4(C), 141.4(C),




(7a). Yield 66%, mp 190–192 C, 1H NMR (500 MHz, CDCl3) d 8.07
(d, J ¼ 7.8 Hz, 2H, Ar.), 7.46 (t, J ¼ 7.9 Hz, 2H, Ar.), 7.36 (t, J ¼
7.4 Hz, 1H, Ar.), 6.48 (dd, J ¼ 5.5, 2.9 Hz, 1H), 6.28 (dd, J ¼ 5.3,
3.1 Hz, 1H), 4.56 (m, 3H), 3.58 (s, 1H), 3.30 (s, 1H), 2.70 (d, J ¼
9.0 Hz, 1H), 1.54 (s, 2H), 1.50 (t, J¼ 7.1 Hz, 3H, CH2CH3). 13C NMR
(126 MHz, CDCl3) d 176.8(C]O), 156.3(C]O), 154.1(C),
140.3(CH), 137.7(C), 136.1(C), 134.3(CH), 129.1(CH), 128.2(CH),




(7b). Yield 69%, mp 191–193 C, 1H NMR (500 MHz, CDCl3) d 7.93
(d, J¼ 8.1 Hz, 2H, Ar.), 7.25 (d, J¼ 8.1Hz, 2H, Ar.), 6.47 (s, 1H), 6.27
(s, 1H), 4.53–4.57 (m, 3H), 3.58 (s, 1H), 3.29 (s, 1H), 2.69 (d, J ¼
9.0 Hz, 1H), 2.38 (s, 3H, p-tolyl), 1.53 (s, 2H), 1.49 (t, J¼ 7.1 Hz, 3H,
CH2CH3).
13C NMR (126 MHz, CDCl3) d 176.7(C]O), 156.4(C]O),
153.9(C), 140.5(CH), 138.1(C), 137.5(C), 134.3(CH), 133.7(C),
130.1(CH), 122.2(CH), 63.5(CH2), 57.3(CH), 52.9(CH), 49.5(CH),
43.7(CH2), 40.5(CH), 21.0(CH3, p-tolyl), 14.0(CH3).
Ethyl (4aS*,5S*,8R*,8aR*)-1-(4-nitrophenyl)-9-oxo-
1,4a,5,8,8a,9-hexahydro-5,8-methano[1,2,4]triazolo[4,3-a]
quinazoline-3-carboxylate (7c). Yield 60%, mp 238–240 C, 1H
NMR (500 MHz, CDCl3) d 8.51 (d, J¼ 9.2 Hz, 2H, Ar.), 8.32 (d, J¼
9.2 Hz, 2H, Ar.), 6.49 (dd, J ¼ 5.5, 2.9 Hz, 1H), 6.29 (dd, J ¼ 5.3,
3.1 Hz, 1H), 4.6–4.55 (m, 3H), 3.59 (s, 1H), 3.30 (s, 1H), 2.72 (d, J
¼ 9.0 Hz, 1H), 1.58–1.5 (m, 5H). 13C NMR (126 MHz, CDCl3)
d 176.6(C]O), 156.0(C]O), 154.4(C), 146.1(C), 141.2(C),
140.2(CH), 138.5(C), 134.4(CH), 124.7(CH), 121.6(CH),




carboxamide (7d). Yield 60%, mp 224–226 C, 1H NMR (500
MHz, CDCl3) d 8.87 (s, 1H, NH), 7.92 (d, J¼ 8.1 Hz, 2H, Ar.), 7.69
(d, J¼ 7.9 Hz, 2H, Ar.), 7.43 (t, J¼ 7.7 Hz, 2H, Ar.), 7.31–7.20 (m,
3H, Ar.), 6.51–6.39 (m, 1H), 6.37–6.27 (m, 1H), 4.61 (d, J ¼
9.0 Hz, 1H), 3.55 (s, 1H), 3.44 (s, 1H), 2.68 (d, J ¼ 8.9 Hz, 1H),
2.37 (s, 3H, p-tolyl), 1.52 (s, 2H). 13C NMR (126 MHz, CDCl3)
d 176.8(C]O), 154.0(C]O), 153.0(C]O), 139.9(CH), 139.4(C),
138.3(C), 136.1(C), 134.8(CH), 133.5(C), 129.7(CH), 129.4(CH),




Yield 45%, mp 118–120 C, 1H NMR (500 MHz, CDCl3) d 7.96 (d,This journal is © The Royal Society of Chemistry 2020J¼ 8.5 Hz, 2H, Ar.), 7.27 (d, J¼ 8.1 Hz, 2H, Ar.), 6.45 (dd, J¼ 5.4,
2.9 Hz, 1H), 6.30 (dd, J ¼ 5.3, 3.1 Hz, 1H), 4.51 (d, J ¼ 8.9 Hz,
1H), 3.55 (s, 1H), 3.18 (s, 1H), 2.72 (s, 3H, COCH3), 2.65 (d, J ¼
9.0 Hz, 1H), 2.39 (s, 3H, p-tolyl), 1.57–1.42 (m, 2H). 13C NMR
(126 MHz, CDCl3) d 187.7(C]O), 176.7(C]O), 154.1(C),
142.1(C), 140.0(CH), 138.1(C), 134.7(CH), 133.8(C), 129.7(CH),




quinazoline-3-carboxylate (7f). Yield 77%, mp 185–187 C, 1H
NMR (500 MHz, CDCl3) d 7.92 (d, J¼ 9.0 Hz, 2H, Ar.), 6.95 (d, J¼
9.0 Hz, 2H, Ar.), 6.47 (dd, J ¼ 5.4, 2.8 Hz, 1H), 6.27 (dd, J ¼ 5.2,
3.1 Hz, 1H), 4.60–4.46 (m, 3H), 3.83 (s, 3H, OCH3), 3.57 (s, 1H),
3.29 (s, 1H), 2.68 (d, J ¼ 9.0 Hz, 1H), 1.53 (s, 2H), 1.49 (t, J ¼
7.1 Hz, 3H, CH2CH3).
13C NMR (126 MHz, CDCl3) d 176.8(C]O),
159.0(C]O), 156.3(C), 153.7(C), 140.4(CH), 137.4(C), 134.3(CH),
129.1(C), 123.9(CH), 114.2(CH), 63.3(CH2), 57.3(CH), 55.5(CH),
52.8(CH), 49.7(CH), 43.9(CH2), 40.5(OCH3), 14.1(CH3).
Ethyl (4aS*,5S*,8R*,8aR*)-1-(4-chlorophenyl)-9-oxo-
1,4a,5,8,8a,9-hexahydro-5,8-methano[1,2,4]triazolo-[4,3-a]
quinazoline-3-carboxylate (7g). Yield 68%, mp 218–224 C, 1H
NMR (500 MHz, CDCl3) d 8.11 (d, J¼ 8.9 Hz, 2H, Ar.), 7.43 (d, J¼
8.9 Hz, 2H, Ar.), 6.48 (dd, J ¼ 5.5, 2.9 Hz, 1H), 6.28 (dd, J ¼ 5.4,
3.1 Hz, 1H), 4.59–4.50 (m, 3H), 3.58 (s, 1H), 3.29 (s, 1H), 2.70 (d, J
¼ 9.0 Hz, 1H), 1.53 (d, J ¼ 7.9 Hz, 2H), 1.50 (t, J ¼ 7.1 Hz, 3H,
CH2CH3).
13C NMR (126 MHz, CDCl3) d 176.6(C]O), 156.1(C]
O), 154.0(C), 140.3(CH), 137.8(C), 134.8(C), 134.3(CH), 133.6(C),
129.2(CH), 123.1(CH), 63.5(OCH2), 57.3(CH), 52.8(CH),
49.7(CH), 43.9(CH2), 40.4(CH), 14.1(CH3).
Ethyl (4aS*,5S*,8R*,8aR*)-1-(3-(triuoromethyl)phenyl)-9-
oxo-1,4a,5,8,8a,9-hexahydro-5,8-methano[1,2,4]triazolo-[4,3-a]
quinazoline-3-carboxylate (7h). Yield 67%, mp 160–162 C, 1H
NMR (500 MHz, CDCl3) d 8.61–8.48 (m, 1H, Ar.), 8.25 (s, 1H, Ar.),
7.64–7.57 (m, 2H, Ar.), 6.49 (dd, J¼ 5.5, 2.9 Hz, 1H), 6.29 (dd, J¼
5.4, 3.1 Hz, 1H), 4.61–4.56 (m, 3H), 3.58 (s, 1H), 3.30 (s, 1H), 2.71
(d, J ¼ 9.0 Hz, 1H), 1.58–1.48 (m, 5H). 13C NMR (126 MHz,
CDCl3) d 176.6(C]O), 156.1(C]O), 154.3(C), 140.4(CH),
138.1(C), 136.7(C), 134.5(CH), 131.8(C), 131.7(C), 130.0(CH),
125.4(CH), 124.5(CH), 118.6(CH), 63.7(CH2), 57.3(CH),
53.0(CH), 49.8(CH), 44.0(CH2), 40.3(CH), 14.2(CH3).
Ethyl (4aR*,5S*,8R*,8aS*)-1-phenyl-9-oxo-1,4a,5,8,8a,9-hexa-
hydro-5,8-methano[1,2,4]triazolo[4,3-a]quinazoline-3-
carboxylate (11a). Yield 72%, mp 191–193 C, 1H NMR (500
MHz, CDCl3) d 8.01 (d, J ¼ 7.8 Hz, 2H, Ar.), 7.44 (t, J ¼ 7.9 Hz,
2H, Ar.), 7.33 (t, J ¼ 7.4 Hz, 1H, Ar.), 6.42 (dd, J ¼ 5.5, 2.7 Hz,
1H), 5.94 (dd, J¼ 5.5, 2.7 Hz, 1H), 5.14 (dd, J¼ 10.0, 3.5 Hz, 1H),
4.55 (q, J ¼ 7.1 Hz, 2H, CH2CH3), 3.71 (s, 1H), 3.68 (s, 1H), 3.27
(dd, J¼ 10.0, 3.9 Hz, 1H), 1.58 (dd, J¼ 27.1, 9.3 Hz, 2H), 1.50 (t, J
¼ 7.1 Hz, 3H, CH2CH3). 13C NMR (126 MHz, CDCl3) d 176.8(C]
O), 156.3(C]O), 154.1(C), 140.3(CH), 137.8(C), 136.1(C),
132.1(CH), 129.1(CH), 127.9(CH), 122.2(CH), 63.4(CH2),
57.1(CH), 49.5(CH), 49.4(CH), 46.4(CH2), 41.2(CH), 14.1(CH3).
Ethyl (4aR*,5S*,8R*,8aS*)-1-(4-nitrophenyl)-9-oxo-
1,4a,5,8,8a,9-hexahydro-5,8-methano[1,2,4]triazol[4,3-a]
quinazoline-3-carboxylate (11c). Yield 75%, mp 190–192 C, 1H

































































































View Article Online9.2 Hz, 2H, Ar.), 6.42 (dd, J ¼ 5.4, 2.6 Hz, 1H), 5.97 (dd, J ¼ 5.4,
2.6 Hz, 1H), 5.15 (dd, J ¼ 10.0, 3.4 Hz, 1H), 4.58 (q, J ¼ 7.1 Hz,
2H, CH2CH3), 3.71 (s(broad), 2H), 3.30 (dd, J¼ 10.0, 3.8 Hz, 1H),
1.60 (dd, J ¼ 32.6, 9.4 Hz, 2H), 1.52 (t, J ¼ 7.1 Hz, 3H, CH2CH3).
13C NMR (126 MHz, CDCl3) d 176.7(C]O), 156.0(C]O),
154.5(C), 146.0(C), 141.2(C), 140.4(CH), 138.5(C), 132.2(CH),




carboxamide (11d). Yield 70%, mp 236–238 C, 1H NMR (500
MHz, CDCl3) d 8.90 (s, 1H), 7.85 (d, J¼ 8.3 Hz, 2H, Ar.), 7.71 (d, J
¼ 7.9 Hz, 2H, Ar.), 7.43 (t, J ¼ 7.8 Hz, 2H, Ar.), 7.25 (dd, J ¼ 16.3,
6.2 Hz, 3H, Ar.), 6.38 (d, J ¼ 5.2 Hz, 1H), 5.95 (d, J ¼ 5.1 Hz, 1H),
5.22–5.12 (m, 1H), 3.86 (s, 1H), 3.65 (s, 1H), 3.30–3.18 (m, 1H),
2.37 (s, 3H, p-tolyl), 1.56 (dd, J¼ 22.5, 9.1 Hz, 2H). 13C NMR (126
MHz, CDCl3) d 176.8(C]O), 154.0(C), 153.0(C), 140.1(CH),
139.6(C), 138.1(C), 136.3(C), 133.6(C), 132.4(CH), 129.6(CH),
129.3(CH), 125.7(CH), 121.9(CH), 120.2(CH), 57.2(CH),
49.6(CH), 49.5(CH), 46.4(CH2), 41.2(CH), 21.1(CH3).
(4aR*,5S*,8R*,8aS*)-3-Acetyl-1-(p-tolyl)-9-oxo-1,4a,5,8,8a,9-
hexahydro-5,8-methano[1,2,4]triazolo[4,3-a]quinazoline (11e).
Yield 50%, mp 210–212 C, 1H NMR (500 MHz, CDCl3) d 7.89 (d,
J¼ 8.4 Hz, 2H, Ar.), 7.25 (d, J¼ 8.3 Hz, 2H, Ar.), 6.39 (s, 1H), 5.90
(s, 1H), 5.10 (d, J¼ 10.0 Hz, 1H), 3.66 (s, 2H), 3.25 (d, J¼ 13.4 Hz,
1H), 2.72 (s, 3H), 2.38 (s, 3H), 1.57 (dd, J ¼ 20.6, 9.2 Hz, 2H). 13C
NMR (126 MHz, CDCl3) d 187.6(C]O), 177.0(C]O), 154.1(C),
142.3(C), 140.2(CH), 138.1(C), 133.7(C), 132.2(CH), 129.7(CH),
121.9(CH), 57.1(CH), 49.5(CH), 49.3(CH), 46.3(CH2), 41.2(CH),
26.6(COCH3), 21.1(CH3, p-tolyl).RDA protocol for the synthesis of [1,2,4]triazolo[4,3-a]
pyrimidines 4a–h
Norbornene-fused [1,2,4]triazolo[4,3-a]pyrimidinones 7a–h or
11a,c–e (0.1 mmol) was dissolved in 1,2-DCM (2 mL) in a 10 mL
sealed reaction vial. The solution was stirred at 200 C for 30–
120 min. at max. 200 Wmicrowave irradiation. Aer completing
the reaction, monitored by TLC, the solvent was evaporated, the
residue was dissolved in EtOAc and puried by column chro-
matography on silica gel eluting with EtOAc.
Ethyl 7-oxo-1-phenyl-1,7-dihydro[1,2,4]triazolo-[4,3-a]
pyrimidine-3-carboxylate (4a). Yield 42% from 7a, 52% from
11a, mp 215–218 C, 1H NMR (500 MHz, CDCl3) d 8.64 (d, J ¼
7.9 Hz, 1H, H-5), 8.19 (d, J ¼ 7.9 Hz, 2H, Ar.), 7.51 (d, J ¼ 7.9 Hz,
2H, Ar.), 7.39 (t, J¼ 7.4 Hz, 1H, Ar.), 6.50 (d, J¼ 7.8 Hz, 1H, H-6),
4.59 (q, J ¼ 7.2 Hz, 2H, CH2CH3), 1.51 (t, J ¼ 7.1 Hz, 3H,
CH2CH3).
13C NMR (125 MHz, CDCl3) 168.5(C]O), 156.2(C]O),
149.2(C), 135.9(C), 132.4(C), 130.6(CH), 129.4(CH), 128.2(CH),
121.4(CH), 114.9(CH), 63.9(OCH2), 14.2(CH3).
Ethyl 7-oxo-1-(p-tolyl)-1,7-dihydro[1,2,4]triazolo[4,3-a]
pyramidine-3-carboxylate (4b). Yield 54%, mp 193–195 C, 1H
NMR (500 MHz, CDCl3) d 8.63 (d, J ¼ 7.7 Hz, 1H, H-5), 8.05 (d, J
¼ 8.6 Hz, 2H, Ar.), 7.29 (d, J¼ 7.9 Hz, 2H, Ar.), 6.49 (d, J¼ 7.8 Hz,
1H, H-6), 4.58 (q, J ¼ 7.2 Hz, 2H, CH2CH3), 2.40 (s, 3H, p-tolyl),
1.50 (t, J ¼ 7.2 Hz, 3H, CH2CH3). 13C NMR (126 MHz, CDCl3)
d 168.5(C]O), 156.2(C]O), 149.1(C), 138.3(C), 133.4(C),33942 | RSC Adv., 2020, 10, 33937–33943132.2(C), 130.5(CH), 129.8(CH), 121.3(CH), 114.9(CH),
63.8(OCH2), 21.1(CH3), 14.1(CH3).
Ethyl 1-(4-nitrophenyl)-7-oxo-1,7-dihydro[1,2,4]triazolo-
[4,3-a]pyrimidine-3-carboxylate (4c). Yield 41% from 7c, 45%
from 11c, mp 205–207 C. 1H NMR (500 MHz, CDCl3) d 8.66 (d, J
¼ 7.6 Hz, 1H, H-5), 8.59 (d, J ¼ 9.7 Hz, 2H, Ar.),8.37 (d, J ¼
9.2 Hz, 2H, Ar.), 6.53 (d, J ¼ 7.6 Hz, 1H, H-6), 4.61 (q, J ¼ 7.2 Hz,
2H, CH2CH3),1.53 (t, J ¼ 7.3 Hz, 3H, CH2CH3). 13C NMR (126
MHz, CDCl3) d 168.0(C]O), 155.8(C]O), 149.3(C), 146.3(C),
140.7(C), 133.2(C), 130.8(CH), 125.0(CH), 120.9(CH), 114.9(CH),
64.2(OCH2), 14.1(CH3).
7-Oxo-N-phenyl-1-(p-tolyl)-1,7-dihydro[1,2,4]triazolo[4,3-a]
pyrimidine-3-carboxamide (4d). Yield 78% from 7d, 67% from
11d, mp 253–255 C, 1H NMR (500 MHz, CDCl3) d 8.85 (d, J ¼
7.9 Hz, 1H, H-5), 8.77 (br, 1H, NH), 8.01 (d, 2H, J ¼ 8.2 Hz, Ar.),
7.69 (d, J¼ 8.0 Hz, 2H, Ar.), 7.40–7.48 (m, 3H, Ar.), 7.27–7.33 (m,
2H, Ar.), 6.49 (d, J¼ 7.9 Hz, 1H, H-6), 2.41 (s, 3H, CH3). 13C NMR
(126 MHz, CDCl3) d 168.6(C]O), 152.9(C]O), 138.4(C),
135.8(C), 134.0(C), 133.3(C), 131.1(CH), 130.5(CH), 129.9(CH),
129.4(CH), 127.7(CH), 126.0(CH), 121.1(CH), 120.4(CH),
114.7(CH), 21.1(CH3).
3-Acetyl-1-(p-tolyl)-[1,2,4]triazolo[4,3-a]pyrimidin-7(1H)-one
(4e). Yield 90% from 7e, 57% from 11e, mp 216–217 C. 1H NMR
(500 MHz, CDCl3) d 8.70 (d, J ¼ 7.8 Hz, 1H, H-5), 8.05 (d, J ¼
8.4 Hz, 2H, Ar.), 7.31 (d, J ¼ 8.7 Hz, 2H, Ar.), 6.46 (d, J ¼ 7.8 Hz,
1H, H-6), 2.77 (s, 3H, COCH3), 2.41 (s, 3H, p-tolyl).
13C NMR (126
MHz, CDCl3) d 187.8(C]O), 168.5(C]O), 149.1(C), 138.5(C),
136.8(C), 133.5(C), 131.1(CH), 129.9(CH), 121.1(CH), 114.9(CH),
26.4(CH3), 21.1(CH3).
Ethyl 1-(4-methoxyphenyl)-7-oxo-1,7-dihydro[1,2,4]triazolo-
[4,3-a]pyrimidine-3-carboxylate (4f). Yield 41%, mp 171–175 C,
1H NMR (500 MHz, CDCl3) d 8.63 (d, J ¼ 7.7 Hz, 1H, H-5), 8.04
(d, J ¼ 9.2 Hz, 2H, Ar.), 7.00 (d, J ¼ 9.1 Hz, 2H, Ar.), 6.49 (d, J ¼
7.7 Hz, 1H, H-6), 4.58 (q, J ¼ 7.2 Hz, 2H, CH2CH3), 3.85 (s, 3H,
OCH3), 1.50 (t, J ¼ 7.2 Hz, 3H, CH2CH3). 13C NMR (126 MHz,
CDCl3) d 168.5(C]O), 159.3(C]O), 156.2(C), 149.0(C), 132.1(C),
130.5(CH), 128.8(C), 123.2(CH), 114.9(CH), 114.4(CH),
63.7(OCH2), 55.6(OCH3), 14.1(CH3).
Ethyl 1-(4-chlorophenyl)-7-oxo-1,7-dihydro[1,2,4]triazolo-
[4,3-a]pyrimidine-3-carboxylate (4g). Yield 58%, mp 178–180 C,
1H NMR (500 MHz, CDCl3) d 8.65 (d, J ¼ 7.7 Hz, 1H, H-5), 8.22
(d, J ¼ 8.8 Hz, 2H, Ar.), 7.48 (d, J ¼ 9.1 Hz, 2H, Ar.), 6.55 (d, J ¼
7.5 Hz, 1H, H-6), 4.59 (q, J ¼ 7.3 Hz, 2H, CH2CH3), 1.51 (t, J ¼
7.1 Hz, 3H, CH2CH3).
13C NMR (126 MHz, CDCl3) d 168.3(C]O),
156.1(C]O), 149.1(C), 134.5(C), 133.9(C), 132.5(C), 130.6(CH),
129.5(CH), 122.3(CH), 115.0(CH), 64.0(OCH2), 14.1(CH3).
Ethyl 7-oxo-1-(3-(triuoromethyl)phenyl)-1,7-dihydro[1,2,4]
triazolo[4,3-a]pyrimidine-3-carboxylate (4h). Yield 48%, mp
193–195 C, 1H NMR (500 MHz, CDCl3) d 8.70–8.72 (m, 2H, Ar,
H-5), 8.30 (brs, 1H, Ar.), 7.64–7.69 (m, 2H, Ar.), 6.53 (d, J ¼
7.8 Hz, 1H, H-6), 4.60 (q, J ¼ 7.1 Hz, 2H, CH2CH3), 1.53 (t, J ¼
7.2 Hz, 3H, CH2CH3).
13C NMR (126 MHz, CDCl3) d 168.2(C]O),
156.0(C]O), 149.2(C), 136.4(C), 132.8(C), 130.2(C), 124.7(CH),
124.7(CH), 124.5(CH), 117.8(CH), 117.8(CH), 115.0(CH),


































































































In the present work, we prepared triazolo[4,3-a]pyrimidin-7(1H)-
ones 4a–h. These compounds cannot be prepared by the reac-
tions of thiouracil 1 and hydrazonoyl chloride 2a–h, because
these reactions are regioselective towards [1,2,4]triazolo[4,3-a]
pyrimidin-5(1H)-ones 3a–d. For overcoming this obstacle, we
used diexo 6 or diendo 10 norbornene-condensed
2-thioxopyrimidin-4-ones characterized by two structural
features: (i) the absence of the C]C bond in the pyrimidinone
moiety that ensures the direction of the regioselectivity towards
triazolo[4,3-a]pyrimidin-7(1H)-ones and (ii) the easy removal of
cyclopentadiene by the RDA reaction and the concomitant
rebuilding the C]C bond in the pyrimidinone moiety to obtain
triazolo[4,3-a]pyrimidin-7(1H)-ones 4a–h as the nal products.
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